## Index

| AAAQ model (availability, accessibility, acceptability and quality) | 9, 70  |
| Abarca-Gómez, L | 429  |
| Abbott, F | 18, 135–63, 495  |
| Abbott, K | 4, 511, 521  |
| Abramowitz, S | 86  |
| Abu Sa’Da, C | 255  |
| access, universal access to medicines | 136, 153, 156, 157, 158  |
| Access to Medicines Index | 33  |
| accountability mechanisms | 502, 504, 510–11, 523, 527  |
| and global governance | 38, 39–40, 42, 51, 53  |
| HIV recognition and evolution | 305, 311–12, 316, 319, 321–5, 331  |
| obesity and public health | 439, 440–41, 445, 446  |
| and right to health, state obligations | 74–6  |
| see also transparency policies  |
| actor power, global governance | 43–50  |
| Adams, J | 405  |
| Adams, V | 88  |
| Adede, A | 199, 211  |
| Africa, Network of African People Living with HIV/AIDS (NAP+) | 311  |
| Africa HIV treatment coverage (2015) | 316  |
| African Commission of Human Rights environmental impact assessments | 222  |
| Social and Economic Rights Action Centre v Nigeria | 222  |
| Aginam, O | 5, 10, 11, 267, 269–70, 432  |
| air pollution, international environmental law | 201–2, 204, 219  |
| alcohol | see non-communicable disease prevention, alcohol, harmful, and unhealthy diet, strategies and recommendations to tackle  |
| Alemanno, A | 389, 390, 403, 410, 417, 421, 446, 456, 457  |
| Alma-Ata Declaration | 76  |
| Alston, P | 90, 91, 98, 317  |
| Amrith, S | 26  |
| Andonova, L | 44  |
| Angot, J-L | 272  |
| Anomaly, J | 49  |
| antimicrobial resistance (AMR) communicable disease control | 497–9, 511, 516–17  |
| Global Strategy on Antimicrobial Resistance | 34  |
| antiretroviral treatment, and HIV | 85–6, 311–12, 314–16  |
| armed conflicts, and international humanitarian law | 239, 241–2  |
| ASEAN Agreement on Transboundary Haze Pollution | 219  |
| Attaran, A | 508  |
| Australia, JTI International v Commonwealth of Australia | 383  |
| Austria, National Nutrition Action plan | 442–3  |
| autonomy and paternalism, tension between, and right to health | 67–9  |
| avian (bird) flu pandemic, communicable disease control | 285–8, 499–500  |
| Backman, G | 57, 316  |
| Baker, M | 273  |
530  Research handbook on global health law

Ban, J 291
Bangladesh, Nurul Islam v
  *Government of Bangladesh* 372
Barnett, M 45
Barona, J-L 465
Barral, V 216
Barreiro-Hurlé, J 403
Bartlett, O 402
Baschuk, B 376
Basel Convention on the Control of
  Transboundary Movements of
  Hazardous Wastes 225–6
Baumberg, B 502
Baxter, R 491, 520
Bayer, R 454
Baytor, T 373
Beauchamp, T 60
Behdinan, A 498, 499, 511
Beitz, C 61, 71
Bélanger, M 12, 270, 271
Bellal, A 8, 18, 20, 239–63
Berman, A 32, 44, 513, 527
Bermann, G 108
Berne Convention on Literary and
  Artistic Works 136, 137
Bettcher, D 377, 411
Biehl, J 84, 86, 88, 102
Biersteker, T 34
Bilano, V 25
bilateral investment treaties (BITs),
  international investment law
  166–7, 168, 169–70, 171, 172,
  173–4, 178–9
Bill and Melinda Gates Foundation
  357
Billaud, J 97
biologic products, and intellectual
  property rights 138, 139, 141,
  142, 144–5, 149
biological standardization,
  pharmaceutical standards
  harmonization 464–5
bird (avian) flu pandemic,
  communicable disease control
  285–8, 499–500
Birnie, P 207, 212, 213, 214, 215,
  216, 218, 220, 221
Bloomberg Philanthropies 357
Blouin, C 129
Blum, R 467
Bogart, W 454
Boisson de Chazournes, L 213, 233,
  273
Bolar exception, patents,
  pharmaceutical products 154–5
Bole, T 60
Bonderson, W 60
Bosworth, M 88
bound tariff rates, international trade
  law, WTO GATT Agreement
  110–11
Boyland, E 404, 405
Boyle, A 432, 490, 520
Brassart Olsen, C 13, 22, 404, 427–59
Breitegger, A 253, 254, 258
Brown, C 175
Brown, T 26
Brundtland, G 291, 346
Brussels Agreement, pharmaceutical
  standards harmonization 464
Buchanan, A 60
Burci, G 2, 3–4, 9, 12, 89, 271, 272,
  288, 290, 294, 295, 431,
  486–528
Button, C 118
Cabrera, O 372, 373, 374, 419
Cairns, G 404, 440
Calo, R 403
Canada
  *AstraZeneca v Apotex* 161
  *Canada (Attorney General) v
  JTI-Macdonald Corp* 383, 385
North American Free Trade
  Agreement (NAFTA) 108,
  159–61
Carballo, J 374
Caribbean Community (CARICOM)
  non-communicable diseases 391
  obesity concerns 411–12
Carreno, I 456
Cassese, A 242
Catalan, E 8
Cataldi, G 288
Cecchini, M 451
Index 531

Celkis, P 60
Chaloupka, F 411
Chamas, C 49
Chan, S 88
Chapman, A 57
Charlesworth, H 97
Chavez, J 377

childhood obesity
and public health see obesity and public health, childhood obesity prevention
children, Convention on the Rights of the Child (CRC) see Convention on the Rights of the Child (CRC)
children and elderly, effects of environment on 201, 204–5
Chinkin, C 432, 523, 524
cholera 43, 52, 90–91, 269
Chung-Hall, J 367


civilians, wounded and sick, international humanitarian law 247–9
Clapham, A 57
Clark, W 40–41
climatic change as a threat to human health 202–5
clinical setting issues, Gostin’s Global Health Law 95–6, 100
clinical trial data, and trade secret protection 149–50
Clinton, C 90
Coco, A 260
Codex Alimentarius Commission 123, 436, 455–6, 489, 490, 498, 521, 526


Coggon, J 88
color and design protection copyright 148
trademarks 146–7
combatants, wounded and sick, international humanitarian law 245–6
commercial expression, obesity and human rights 452–3
commercial rights and interests in regional and domestic law, tobacco epidemic 383–6
communicable disease control 20–21, 265–302, 495, 496, 497–501
antimicrobial resistance (AMR) 497–9, 511, 516–17
bird (avian) flu pandemic 285–8, 499–500
cholera 43, 52, 90–91, 269
classification of diseases 266–7
future directions 297–302, 497–501
global public health threat 265–9
HIV/AIDS pandemic 292–3
integrated global alert and response system (GAR) 276
International Covenant on Civil and Political Rights, Siracusa Principles 288–90
International Health Regulations (IHR) 268, 271–2, 273–8, 495, 501, 513–14
international law evolution 269–72
International Sanitary Regulations 270–71
multilateral pathogen sharing proposal 499–501, 511, 516
National IHR Focal Points 275
non-governmental sources of information 274–5
normative perspective 269, 270
poliovirus outbreak 280
pregnancy bans 284
public health emergency of international concern (PHEIC) 274–5, 276–7
public health emergency of international concern (PHEIC), responses to declared 278–84, 285–6
quarantine measures 269, 270–71, 280, 282
scientific principles and evidence, importance of 279
swine flu pandemic 279–80, 285–8
transparency policies 301
travel restrictions 280–83
WHO, establishment of 270–71
WHO Global Action Plan 498–9
WHO IHR Contact Points 275
WHO International Health Regulations 268
World Health Assembly (WHA), International Health Regulations 273–8
World Health Assembly (WHA), International Health Regulations, Emergency Committee 277
World Health Assembly (WHA), International Health Regulations, Review Committee 277–8, 298, 299–302
Zika virus outbreak 283–4
communicable disease control, health-security paradigm 269, 272, 278, 291–7
non-compliance issues 295–7, 299, 300–302
possible UN action in response to global security threat 295–7
threat to international peace and security interpretation 291–2
and UN Security Council 292–7
communicable disease control, human rights issues 268–9, 274, 275, 278–90, 295–6
impact assessment suggestion 300
and international human rights law 284–90
and international human rights law, derogation and limitation clauses 285–90, 299–300
jus cogens rights 285, 296
compensation, expropriation clause, international investment law 185–6
competition law, intellectual property rights 149, 150–51
computer software protection, and copyright 148
constructivism 517, 521–2
consumer empowerment, and ‘information paradigm’, non-communicable disease prevention 402–3
contouring law, Gostin’s Global Health Law 98–103
Cook, R 8
Cooper, A 53
cooperation international cooperation, WHO Framework Convention on Tobacco Control (FCTC) 349–50
international cooperation and right to health 76–7
copyright see intellectual property rights, copyright
Costello, A 203–4
Cowan, J 97
Cranston, M 63
cross-border movement, global health law 29, 30, 31
Crow, M 419
cultural barriers, HIV recognition and evolution 307
customs unions, international trade law 109
Cuthbert, M 463
Daniels, N 60
Davies, S 28
Davis, S 322
De Albuquerque, C 453
De Búrca, G 92, 101
De Hoogh, A 8
De Luce, D 43
De Mulder, J 221–2
De Sadeleer, N 218
De Schutter, O 440, 444–5
Decade of Healthy Ageing 395
decision-making processes, global governance mechanisms 37, 39
Deland, K 390
Denmark, obesity prevention 449, 457
Dentico, N 506
developing country’s failure to provide adequate patent protection for pharmaceutical products 153–5
Dewan, A 39
Dhurandhar, N 440
discrimination rules prohibition, non-communicable disease prevention 413–14 and stigma, HIV recognition and evolution 307–8, 323–4 discriminatory taxes prohibition, WTO GATT Agreement 112 discursive type, global governance, power types 46–7, 48 Dolzer, R 166, 168, 171, 173, 174, 190, 191 Doswald-Beck, L 244, 248 Drane, J 60 Dresler, C 419, 441 Drope, J 377 drug regulatory authority (DRA), patents and legislative link with marketing approval process of 143, 144 Dudai, R 261
due diligence, and preventative approach, international environmental law 218–19, 222 Duger, A 102 Dunant, H 243, 245 Dunoff, J 104 Duvall, R 45
534  Research handbook on global health law

Philip Morris v Secretary of State for Health 356, 385, 399, 421

Rewe Zentral v Bundesmonopolverwaltung fur Branntwein 457

European Directorate for the Quality of Medicines and Healthcare 467, 473

European Medicines Agency 477

expert type, global governance, power types 46, 47–8

expropriation clause, international investment law 173, 185–90

extreme weather events, international environmental law 204, 205

Ezer, T 95

Faden, R 60

fair and equitable treatment (FET) guarantee

ternational investment law 190–95

'margin of appreciation' concept 194

and Neer standard 173–4

Farha, L 90

Farmer, P 89

Fassin, D 87

Ferraz, O 76

Fidler, D 11, 28, 239, 269, 272, 273, 275, 278, 492, 499

Finnemore, M 33, 517–18

food composition and availability of healthy food, obesity prevention measures 437–8

food industry involvement issues, obesity and public health 440

food safety measures, WTO Sanitary and Phytosanitary Measures (SPS Agreement) 118, 119

Ford, N 506

Forman, L 57

Foster, N 412

Franck, S 177

free trade agreements (FTAs) 107, 108, 109

with TBT-plus commitments, WTO Technical Barriers to Trade (TBT Agreement) 129, 133

Freeman, M 2

Frenk, J 5, 26, 27, 29, 30, 32, 33

Friant-Perrot, M 402

future directions communicable disease control 297–302, 497–501

global health law 519–27

HIV recognition and evolution 326–8

non-communicable disease prevention 502–3, 510, 512

patents, pharmaceutical products 162–3

pharmaceutical standards harmonization 504–6, 511

Garde, A 11, 13, 18, 20, 22, 389–426, 446, 454, 456, 457
general principles 7–8, 19
generic names for pharmaceuticals, and trademarks 146

Geneva Conventions, international humanitarian law 242–3, 244–9, 250, 252, 253–4, 257–8

Giacca, G 240, 249, 258

Giorgetti, C 18, 19, 164–96, 490, 495, 510

Global AIDS Response Progress Reporting (GARPR) framework 323, 324
global alert and response system (GAR), communicable disease control 276

Global Fund to Combat AIDS, Tuberculosis and Malaria (GFATM) 41–2, 312, 321–2

Global G.A.P. (Global Agricultural Practice) 490
global governance 24–54, 503–8, 510

actor power 43–50

actor power, non-state actors 44–5

actor power, state actors 43–4, 49
definition 27

functions and role of law 50–54
Index 535

global health definition 25–7
‘global health governance’ and ‘global governance for health’, distinction between 27–8
global health and international health comparison 25–6 and health, relationship between 27–8
intergovernmental organizations (IGOs) 44
management of externalities across countries 51, 52
mobilization of global solidarity and aid activities 51, 53
production of global public goods (GPGs) 51–2, 54
stewardship 51, 53–4
transparency policies 39

global governance, global health law 28–36
binding formal norms 34–5
codes of behaviour 34
cross-border movement 29, 30, 31
degree to which law should be considered global 31–2
global strategies 34
health law concept 32–3
law concept 33–6
normative instruments 33–5
voluntary formal norms 33–4
global governance, power types 45–50
compulsory 45, 47–8
discursive 46–7, 48
economic 45, 47, 48
expert 46, 47–8
institutional 46, 47, 48
normative 46, 47
structural 45, 47
global governance, role, law and global governance mechanisms 24–5, 36–43
accountability mechanisms 38, 39–40, 42, 51, 53
codified formal and informal rules 37, 38
decision-making processes 37, 39
human resources 42
ideational/framing tools 38, 40–41
normative claims 37, 38–9
physical force 38, 42–3
relationship between 37–43
resource mobilization 38, 41–2
global health law, present and future 486–528
changing perceptions of health 494–508
communicable diseases 497–501
constructivism 517, 521–2
future forecast 519–27
globalization effects 494–5
health governance issues 503–8
health treaties 508–19
health treaties, factors against 512–19
health treaties, factors in favour of new 509–12
informal international law-making 491, 513, 519–20
legalization of global governance 517–18, 519, 524
new health treaties 495–508
non-communicable diseases 496–7, 502–3
normative landscape on health 487–93
normative landscape on health, and soft law 489–92, 513, 520, 521–2, 524, 526
Global Influenza Surveillance and Response System (GISRS) 499
Global Strategy on Antimicrobial Resistance 34
Global Strategy on Diet, Physical Activity and Health 394
Global Strategy on HIV/AIDS 308–9
Global Strategy for Infant and Young Child Feeding 394
Global Strategy to Reduce the Harmful Use of Alcohol 394
Global Strategy for Women’s, Children’s and Adolescents’ Health 395
globalization effects
global health law, present and future 494–5
populist backlash against
globalization 108
Gloppen, S 102
Godue, C 26
Goffman, E 453
Golding, M 60
Gortmaker, S 440
Gostin, L 2, 7, 10, 12, 15, 24, 28, 29, 66–7, 64, 78, 81, 82–3, 85, 89, 104, 271, 273, 284, 372, 390, 419, 492, 496, 497, 502, 503–4, 523
human rights perspective see human
rights perspective, hardwired,
Gostin’s Global Health Law
Green, J 89
Green, L 246
Greer, S 193
Griffin, J 61, 64, 67, 71
Groc, N 78
Grodin, M 83
Gross, A 60
Grover, A 406, 440
Grunert, K 403
Gruskin, S 13, 14, 20, 21, 83, 303–39, 492, 495
Hague Regulations and methods of
warfare 244
Haines, A 203
Haiti, cholera outbreak 90–91
Hale, T 32
Hall, R 34
Hallgath, L 312
Handsley, E 419
harmonization
pharmaceutical standards see
pharmaceutical standards
harmonization
support, WTO Sanitary and
Phytosanitary Measures (SPS
Agreement) 123
Harrington, J 14
Hartlev, M 9, 13, 22, 404, 427–59
Hawkes, C 411, 435, 455, 456, 457
health, right to see right to health
health sector control issues, WHO
Framework Convention on
Tobacco Control (FCTC) 368–9
health treaties 508–19
new 495–508
health-security paradigm,
communicable disease control
see communicable disease
control, health-security paradigm
Heimer, C 101
Hein, W 36–7, 40
Heiser, V 465
Helfer, L 525
Henckaerts, J-M 244, 248
Hendriks, A 14, 15, 17
Hessler, K 60
Heuer, C 429, 453
high in fat, salt and sugar (HFSS)
foods, obesity and public health
429, 436, 437, 448
Hilleman, M 465
HIV recognition and evolution 21,
303–39, 492, 495, 523–4
accountability mechanisms 305,
311–12, 316, 319, 321–5, 331
Africa treatment coverage (2015)
316
antiretroviral treatment (ART)
access 85–6, 311–12, 314–16
antiretroviral treatment (ART)
access, cost reduction 315–16
communicable disease control
292–3
cultural barriers and prevention
methods 307
future directions 326–8
Global AIDS Response Progress
Reporting (GARPR)
framework 323, 324
Global Fund to Combat AIDS,
Tuberculosis and Malaria
(GFATM) 312, 321–2
global and national policies and
human rights framework
316–21
Global Strategy on HIV/AIDS
308–9
human rights principles, incorporation of 84–7, 304–21, 326–39
international monitoring mechanisms 321–5
international monitoring mechanisms, UN Treaty Monitoring Bodies (TMBs) 324–5
Key Populations support 308, 324, 326–7
linkages to health and human rights prior to emergence of HIV 304–6
Médecins Sans Frontières (MSF) 306
Network of African People Living with HIV/AIDS (NAP+) 311
NGO involvement in health and human rights issues 305–6, 312
normative perspective 304, 306–16, 324, 325, 326
prevention, care and treatment, schematic differentiation 318–19
research and programming investment 308–9
research versus prevention resource issues 313–14
right to health 325, 330, 331, 334
risk-reduction approaches 309, 310–12
state denials of existence of HIV 307, 308
state obligations 317–19
stigma and discrimination issues 307–8, 323–4
transparency policies 321–5, 331
tri-therapy effectiveness 310–11
UN General Assembly Special Session (UNGASS) Declaration 322–3
UN Millennium Development Goals 317, 319
UN Program on HIV/AIDS (UNAIDS) 310, 311, 312, 313, 314, 317, 322–3, 326, 523–4
UN Program on HIV/AIDS (UNAIDS), National Commitments and Policy Instrument (NCPI) 322
UN Sustainable Development Goals (SDGs) 319–20, 326
US President’s Emergency Plan for AIDS Relief (PEPFAR) 312, 321
vulnerability-reduction responses 309, 311–12
WHO discord and setbacks 313
WHO HIV Progress report 315, 316, 323
WHO Special Programme on AIDS 308–9, 313, 314
Hodge, J 288
Hoffman, S 498–9, 509, 511, 519
holistic response, need for, right to health 80
Holle, M 456
Horaud, F 465
Horton, R 88, 89
hospitals and medical personnel protection, international humanitarian law 252–5
Hovell, D 91
Howells, G 403
Hoyle, C 88
Huffman, S 12
human rights 6–7, 9, 13–17
communicable disease control see communicable disease control, human rights issues
HIV recognition and evolution 84–7, 304–21, 326–39
Human Rights Council’s Open-Ended Working Group on Transnational Businesses 373
Inter-American Commission on Human Rights 373
Inter-American Court of Human Rights, De La Cruz-Flores v Peru 260

Index 537
non-communicable disease prevention 418–22
and obesity see obesity and public health, human rights
human rights perspective, hardwired 13–17, 82–103
cholera outbreak, Haiti 90–91
global health law issues 87–91
global health law issues and common attitude 89–90
global health law issues, international rule of law, disillusionment with 90–91
global health law labels 88–9
HIV/AIDS pandemic 84–7
HIV/AIDS pandemic, universal access to antiretroviral (ARV) treatment 85–6
litigation debates 84, 101–2
medical humanitarianism 86
normative perspective 88, 96, 97, 98–9, 100, 101
origins 84
public health crises 85–7
right to science 94
state decision-making, court techniques and doctrines of deference 97, 101–2
human rights perspective, hardwired, Gostin’s Global Health Law 91–103
and clinical setting issues 95–6, 100 collective versus individual right 94–5
contouring law 98–103
economic and social rights as imprecise, and progressive realization 96–8
as an endeavour 99
with governance 99, 100
interpretation issues 100–101
law’s inherent limitations 99
and non-law settings 102
precise right to health, misplaced quest 101–2
right to health 93–6
see also Gostin, L

humanitarian law see international humanitarian law
Hunt, P 57, 79, 93, 316
ideational/framing tools, global governance mechanisms 38, 40–41
illicit trade in falsified medicines 506–8, 512
illicit trade in tobacco products 351–2
impact assessment
expert group, tobacco epidemic 364–8
international environmental law 221–3, 226–7
suggestion, communicable disease control 300
India
Kerala Voluntary Health Services v Union of India 374
Murli S Deora v Union of India 372
Patents Act 141–2
Ramakrishnan v State of Kerala 372
industry voluntary commitments, non-communicable disease prevention 409
influenza
avian (bird) flu pandemic 285–8, 499–500
Pandemic Influenza Preparedness Framework (PIP Framework) 12–13
swine flu pandemic 279–80, 285–8
informal international law-making 491, 513, 519–20
information access
and copyright 147–8
‘information paradigm’ and ‘consumer empowerment’, non-communicable disease prevention 402–3
non-governmental sources, communicable disease control 274–5
obesity and public health, prevention measures 435–6
see also interpretation issues
Inrig, S 308, 310, 313
institutional type, global governance, power types 46, 47, 48
integrated global alert and response system (GAR), communicable disease control 276
intellectual property protection, international investment law 172
intellectual property rights 135–63, 495, 509–10, 525–6
competition law 150–51
economic analysis limits 161–3
exhaustion of rights and parallel imports 151–2
international regulation 135–8
preferential trade agreements (PTAs) 159–61
preferential trade agreements (PTAs), investor to state dispute settlement (ISDS) mechanisms 160–61
preferential trade agreements (PTAs), US free trade agreements 159–60
preferential trade and investment agreements (TRIPS-plus) 136–7
regulatory market exclusivity 143–5
regulatory market exclusivity, new biologic products 138, 139, 141, 142, 144–5, 149
regulatory market exclusivity, patents, distinction from 143–4
tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC) 382
WIPO Madrid Agreement and Protocol (Madrid System) 137
WIPO Patent Cooperation Treaty (PCT) 137
WIPO role 158
World Health Organization (WHO) role 158–9
World Health Organization (WHO) role, delinking R&D element from production and distribution elements 158–9
intellectual property rights, copyright 147–8
color and design protection 148
computer software protection 148
duration 148
information brochures 147–8
research materials 148
intellectual property rights, patents 138–43
inventions 140–41
legislative link with marketing approval process of drug regulatory authority (DRA) 143, 144
patent monopoly 139
Patent Prosecution Highway (PPH) 137
regulatory market exclusivity, patents, distinction from 143–4
third parties prevented from using protected subject matter 142–3
usefulness criteria 142
vaccines 139–40
intellectual property rights, patents, pharmaceutical products 139–42
Bolar exception 154–5
developing country's failure to provide adequate patent protection, and flexibility arrangements 153–5
future research and development 162–3
international exhaustion concerns 155–6
modification of existing compound 141–2
regulatory review exception 154–5
intellectual property rights, trade secret protection 148–50
clinical trial data 149–50
Research handbook on global health law

misappropriation criminalization 150
and reverse engineering 149
and unfair competition 149
intellectual property rights, trademarks 145–7
colors and shapes, protection of 146–7
generic names for pharmaceuticals 146
Madrid System 145–6
intellectual property rights, WTO TRIPS Agreement 39, 136, 137, 143, 144–5, 148–9, 151, 160, 505, 525–6
Doha Declaration and compulsory licenses 156–7, 160
multilateral issues 152–9
and universal access to medicines 136, 153, 156, 157, 158
Inter-American Commission on Human Rights 73
Inter-American Court of Human Rights, De La Cruz-Flores v Peru 260
International Biological Preparations of Reference 471
International Centre for the Settlement of Investment Disputes (ICSID) 168, 175–6
Cargill v United Mexican States 173
EDF v Romania 191
Hussein Nuaman Soufraki v The United Arab Emirates 168–9
Metalclad v United Mexican States 174, 186–7
Noble Ventures v Romania 190–91
Pey Casado v Chile 172
Philip Morris v Uruguay 19, 107, 164, 171–2, 173, 183–5, 189–90, 193–4, 356, 375–6, 378–9, 381, 490
Siag v Egypt 168
International Chemical Reference Substances 470
International Code of Marketing of Breast-milk Substitutes 12, 394, 448, 487
International Committee on Economic Social and Cultural Rights (ESCR Committee) 62, 64–5, 67, 68, 69–70
International Committee of the Red Cross (ICRC), international humanitarian law 243, 248, 250–51, 255, 259
International Committee for Relief to the Wounded, international humanitarian law 243
International Conference of Drug Regulatory Authorities (ICDRA), pharmaceutical standards harmonization 469–70
international cooperation and assistance obligations, tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC) 349–50
International Council on Harmonization (ICH) 32
International Council for Harmonization of Technical Requirements for the Pharmaceuticals for Human Use (ICH) 4–5, 461, 466, 467–8, 521, 527
International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) see pharmaceutical standards harmonization, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
International Court of Justice (ICJ) 7–8
on environmental law 205–6, 214–15, 216–17, 218, 221–2
Index

Gabcikovo-Nagymaros Project (Hungary/Slovakia) 206, 216, 218
Nicaragua v US 243
Nuclear Tests (New Zealand v France) 206, 215
Pulp Mills on the River Uruguay (Argentina v Uruguay) 218, 221–2
International Covenant on Civil and Political Rights (ICCPR) 285, 305, 452
International Criminal Tribunal for the former Yugoslavia (ICTY) Galić 260
Prosecutor v Haradinaj 242
Tadić 241
international environmental law 197–238, 488
2030 Agenda for Sustainable Development 203
air pollution 201–2, 204, 219
Basel Convention on the Control of Transboundary Movements of Hazardous Wastes 225–6
children and elderly, effects of environment on 201, 204–5
climate change as threat to human health 202–5
climate change as threat to human health, health gains as opportunity for action 203
Convention on Biological Diversity, Cartagena Protocol on Biosafety and risk assessments 230–32
Convention on the Law of the Non-Navigational Uses of International Watercourses 233
diseases impacted by environment 201–2
Espoo Convention on Environmental Impact Assessment in a Transboundary Context 226–7
extreme weather events 204, 205
health protection in practice 223–36
human health and well-being 198, 200, 202, 208, 209, 210, 212, 231, 232–3, 234
International Law Commission (ILC), Articles on Transboundary Harm 215, 233
Minamata Convention on Mercury 235–6
normative perspective 206, 215, 216, 217
Paris Agreement 203, 227, 228
Protocol on Water and Health 232
right to water 213
Rio Declaration and Agenda 21, and sustainable development 206, 209–11, 213, 214, 216, 217, 219, 228–9, 232, 234
Rio Declaration and Agenda 21, and sustainable development, primary health needs and preventative efforts 211
Stockholm Conference 197, 206, 207–9, 210, 213, 214, 217
Stockholm Convention on Persistent Organic Pollutant 226, 234
sustainable development 203, 211, 215–17, 221
UN Conference on Sustainable Development 211–12
UN Environment Programme 234
UN Framework Convention on Climate Change (UNFCCC) 202–3, 209, 214, 227–8
UN Sustainable Development Goals 212, 217
UN Water Conference 209
Vienna Convention for the Protection of the Ozone Layer 223–4
Water Charters 234
water contamination 204–5, 209
World Health Organization (WHO) Report 200–201, 202
World Summit on Sustainable Development 211
international environmental law, health and environment link 199–205, 212–23
as a driving force of environmental law 205–12
precautionary principle 219–20, 221, 230
preventative approach 217–19
preventative approach, and due diligence 218–19, 222
preventative approach, state practice 218
sovereignty over natural resources 214–15
transboundary environmental impact assessment, obligation to conduct 221–3, 226–7
International Health Regulations (IHR) 34, 52, 123–4, 487
communicable disease control 268, 271–2, 273–8, 495, 501, 513–14
international humanitarian law 239–63
armed force application conditions 241–2
armed group’s level of organization context 242
Geneva Conventions 242–3, 244–9, 250, 252, 253–4, 257–8
global effects of armed conflicts on health 239
global governance efforts on healthcare 254–6
Hague Regulations and methods of warfare 244
hospitals and medical personnel protection 252–5
International Committee of the Red Cross (ICRC) 243, 248, 250–51, 255, 259
International Committee for Relief to the Wounded 243
Martens Clause 244
non-international armed conflict application 242–3
normative perspective 244, 245, 248, 252, 255–6, 260–62
obligations 249–52
Oxford Guidance on the Law relating to Humanitarian Relief Operations 251
protracted violence context 242
relief operation consent 250–52
international humanitarian law, non-state armed groups and healthcare 256–62
attacks on governmental armed forces in armed conflicts 260
codes of conduct for delivery of healthcare 261
counter-terrorism legislation effects 259–62
human rights obligations 258
incentives to implement 261–2
wounded and sick protection 257–8
wounded and sick provisions, concerns over 260–61
international humanitarian law, wounded and sick civilians 247–9
combatants 245–6
enemy soldiers detained by a state 246
legal regime of occupation and emergency law 248
origins of term 243–5
respect and protect obligations 249–50
search for, collect and ensure adequate care obligations 250–52
state’s own forces 246
international investment law 164–96, 490, 495, 510
bilateral investment treaties (BITs)

case assessments 179–95
case assessments, Chemtura Corporation v Canada 181–3, 188, 191–2
case assessments, Methanex v US
173, 180–81, 187–8, 192–3, 194
case assessments, Philip Morris v Uruguay 19, 107, 164, 171–2, 173, 183–5, 189–90, 193–4, 356, 375–6, 378–9, 381, 490

Single Presentation Requirement (SPR) 184–5, 189, 194

expropriation clause 173, 185–90
expropriation clause, compensation evaluation 185–6
expropriation clause, indirect expropriation 186–90
fair and equitable treatment (FET) guarantee 190–95
fair and equitable treatment (FET) guarantee, ‘margin of appreciation’ concept 194
fair and equitable treatment (FET) guarantee, and Neer standard 173–4
intellectual property protection 172
investment definition 170–73

case assessments, 

legal framework 165–79
margin of appreciation, fair and equitable treatment (FET) guarantee 194

most-favoured-nation (MFN) treatment 175

protection standards 173–5
public health measures 166, 172–3, 177–9, 180–85
regional free trade agreements 167
Salini test 171–2
sectoral treaties 167–8

States’ police and regulatory powers 174, 177, 180, 187, 190, 194
tobacco epidemic 375–83
transparency policies 177, 180, 191

International Law Commission (ILC), Articles on Transboundary Harm 215, 233

International Law Organization (ILO) 10, 11

Occupational Safety and Health Convention 487–8

International Medical Device Regulators Forum 490

International Office of Epizootics 123

International Organization for Standardization (ISO) 489, 521
International Pharmacopoeias and drugs analysis 464, 470, 473
International Plant Protection Convention 123

International Sanitary Conferences 52
International Sanitary Regulations, communicable disease control 270–71


international trade impact, WTO Agreement on Technical Barriers to Trade and pharmaceutical standards harmonization 479–83

international trade law 104–34, 489, 490, 495
customs unions 109
free trade agreements (FTAs) 107, 108, 109
investment treaties 107–8
like products test 111, 126
and non-communicable disease prevention see non-communicable disease prevention, and international trade law
and obesity prevention 455–6
populist backlash against globalization 108
tobacco epidemic 375–83
WHO Codex Alimentarius Commission standards 123, 489
WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 105, 106
WTO dispute settlement 105–7
international trade law, WTO GATS Agreement 105, 129–33
domestic regulation 130–31
general obligations 130–31
market access commitment 131
mutual recognition of domestic standards 131
supply of health services 129–30, 131
international trade law, WTO GATT Agreement 104–5, 109–17
alternative measure consideration 116–17
bound tariff rates 110–11
discriminatory taxes prohibition 112
effectiveness of an intervention 115–16
general exceptions 113–17
human life or health protection 117
like products test 111, 126
measures to protect health 113–14
most-favoured nation (MFN) treatment 110, 126, 130, 132
necessity of a measure as a whole 114–15, 117
non-discrimination–national treatment 111–12
quantitative restrictions 112
threshold question and measure achieving its objective 115
trade restrictiveness determination 114–15
international trade law, WTO Sanitary and Phytosanitary Measures (SPS Agreement) 105–6, 118–25, 490, 498
compliance review 121
exceptions and available pertinent information (precautionary approach) 121–2
food safety measures and measures to prevent risks to health associated with diseases or pests 118, 119
harmonization support 123
international standards, guidelines and recommendations definition 123–4
measures implemented by other Members, and equivalence provision 124–5
necessity test 119, 122
risk assessment 119–23
scientific evidence analysis 119, 120–21
trade restrictive measures, prohibition of 122
international trade law, WTO Technical Barriers to Trade (TBT Agreement) 105, 106, 125–9, 455, 456, 490, 498, 521
free trade agreements (FTAs) with TBT-plus commitments 129, 133
international standards as basis for technical regulations 127–8, 132
mandatory requirements 125–6
necessity test 127–8
non-discrimination requirements 126–7
and pharmaceutical standards 479–83
ratchet clauses 133
standstill clauses 133
trade and health issues focus 128–9, 132
transparency requirements 128–9
International Treaty on Plant Genetic Resources for Food and Agriculture 516
International Tribunal for the Law of the Sea (ITLOS) 221
environmental impact assessments
precautionary principle 220
interpretation issues
human rights perspective, Gostin’s Global Health Law 100–101
right to health 65–6
see also information access
inventions, and patents 140–41
investment law see international investment law
investment treaties, international trade law 107–8
Investor-State Dispute Settlement (ISDS), international investment law 165–6, 175–7
Jacinto, J 166
Jackson, A 262
Jacobs, R 345
James, W 428, 431, 432
Japan, Pharmaceutical and Medical Devices Agency 477
Jernigan, D 404
Jewell, J 458
Jha, P 439
Joint Action and Learning Initiative on National and Global Responsibilities for Health (JALI) 504
jus cogens rights, communicable disease control 285, 296
Kahneman, D 403
Kamrad-Scott, A 301
Karst, K 144
Kaufmann, C 60
Kaufmann-Kohler, G 165
Kay, R 452
Kelly, T 108
Kenya, British American Tobacco Ltd v Cabinet Secretary for the Ministry of Health 383
Key Populations support, HIV recognition and evolution 308, 324, 326–7
Kickbusch, I 28, 496
Kirkland, A 452
Kirton, J 391
Klabbers, J 491, 520
Kolb, R 7
Kopp-Kubel, S 466
Koppe, E 7, 8
Koskenmäki, R 288, 290
Kraak, V 405
Laixuthai, A 411
Lakoff, A 89
Lang, W 207
Langford, M 98, 102, 319
Laporte, J-R 460
Larking, E 97
Lazarus, L 97
Lazzarini, Z 82
Lee, E 430, 431, 438
Lee, K 39
legalization of global governance 517–18, 519, 524
Levy, D 367
Liberman, J 11, 20, 21–2, 340–88, 490, 495, 510, 518–19
Lien, G 390
like products test, international trade law 111, 126
Link, B 453
Livingston, J 96
Lo, B 307
lobbying and governmental resistance, obesity and public health 433
Lowe, V 411
McCrudden, C 92, 101
McDonald, R 8–9
McEvoy, K 261
McGrady, B 17–18, 104–34, 377, 394, 411, 412, 415–16, 454, 455, 489, 490, 495
Machlup, F 161–2
McNeill, D 281

Madrid System, intellectual property rights, trademarks 145–6
Magnusson, R 49, 95, 390, 424, 425, 427
Malik, V 427
Mann, H 180, 192
Mann, J 83, 84, 308–10, 313, 441

margin of appreciation, fair and equitable treatment (FET) guarantee, international investment law 194
market access commitment, international trade law, WTO GATS Agreement 131
marketing authorization, pharmaceutical standards harmonization 462, 463, 466–8
marketing restrictions, non-communicable disease prevention 404–6
Marks, S 419
Marmot, M 395
Martens Clause, international humanitarian law 244
Mason Meier, B 10, 16
Matsushita, M 416
Mavroidis, P 108, 112
Mbengue, M 8, 18, 19, 197–238, 269, 488

Médecins Sans Frontières (MSF) 254, 306
medical personnel protection, international humanitarian law 252–5
medicines, universal access to, and intellectual property rights 136, 153, 156, 157, 158
Meier, B 89, 94
Mercurio, B 165, 172, 177, 179
Merry, S 97, 100
Merson, M 308, 310, 313

Mexico, North American Free Trade Agreement (NAFTA) 108, 159–61
Mikos-Skuza, E 252, 258
Mills, L 419
Minamata Convention on Mercury, international environmental law 235–6
misappropriation criminalization, trade secret protection 150
Model List of Essential Medicines 520, 523
Mohindra, K 345
Mohney, G 284
Moloo, R 166
Mondielli, É 273, 274
monitoring mechanisms, HIV recognition and evolution 321–5
Montero, M 71
Montevideo Road Map, non-communicable disease prevention 389, 401, 409, 422
Moodie, R 410
Moon, S 3, 5, 24–54, 268, 510
moral philosophy, and right to health 61–2, 78–9
Mori, L 94
Morse, J 101
most-favoured-nation (MFN) treatment international investment law 175 international trade law 110, 126, 130, 132
MPOWER measures, WHO Framework Convention on Tobacco Control (FCTC) 366–7, 368
Müller, A 240
multilateral pathogen sharing proposal, communicable disease control 499–501, 511, 516
Murphy, R 246
Murphy, T 7, 14, 15–16, 57, 63, 82–103
Myanmar, Karen National Union (KNU) 261–2
Nagoya Protocol on Access to Genetic Resources 491, 500, 501
Nakajima, H 313

necessity test

non-communicable disease prevention, and international trade law 417–18
WTO Sanitary and Phytosanitary Measures (SPS Agreement) 119, 122
WTO Technical Barriers to Trade (TBT Agreement) 127–8

Neer standard, fair and equitable treatment (FET) guarantee, and international investment law 173–4
Negri, S 12, 20–21, 265–302, 495
Nelson, P 317, 319
Nestle, M 410
Netherlands, Netherlands v Dutch Non-Smokers Association 374
Network of African People Living with HIV/AIDS (NAP+) 311

see also Africa
Ng, M 427, 428
NGO involvement, HIV recognition and evolution 305–6, 312
Niang, I 205
Niezen, R 90
Nikogosian, H 496

Convention on the Rights of the Child (CRC) 419, 420, 421–2
effective policies and multisectoral response 422–5
future proposals 502–3, 510, 512
human rights approach 418–22
legal opportunities 390–410
Montevideo Road Map 389, 401, 409, 422
normative perspective 422–5
obesity in Small Island Developing States (SIDs) 411–12
regulatory tools 396–410
tobacco control, industry interference protection 399–400
tobacco control, legally binding global framework 397–400
tobacco control, legally binding global framework, WHO Framework Convention on Tobacco Control (FCTC) 394, 397–9
tobacco control, WHO Framework Convention on Tobacco Control (FCTC) 359–61
UN 2030 Agenda for Sustainable Development 389
UN High Level Meetings on NCD prevention 391–6
UN InterAgency Task Force on NCDs (IATF) 393
UNICEF, For a Child Rights-Based Approach to Food Marketing 419–20
WHO 2030 Agenda for Sustainable Development 395–6
WHO Global Coordination Mechanism on NCDs (GCM/NCD) 393–4
WHO Global Strategy on Diet and Physical Activity 408–9
WHO Global Strategy to Reduce the Harmful Use of Alcohol 405–6, 408–9
non-communicable disease prevention, alcohol, harmful, and unhealthy diet, strategies and recommendations to tackle 400–410, 502, 503
comprehensive and systematic restructuring of food environment 404–10
industry voluntary commitments 409
‘information paradigm’ and ‘consumer empowerment’ 402–3
marketing restrictions 404–6
measures affecting product availability 406–7
price factors 407–8
taxation rates 407–8
non-communicable disease prevention, and international trade law 410–418
prohibition of discriminatory rules 413–14
public health grounds, justifying necessary trade-restrictive measures 412, 414–18
public health grounds, justifying necessary trade-restrictive measures, and burden of proof 416–17
public health grounds, justifying necessary trade-restrictive measures, necessity assessment 417–18
trade liberalization effects 411–12
and WTO Agreements 415–16
non-compliance issues, communicable disease control 295–7, 299, 300–302
non-discrimination requirements
obesity and public health 453–4
WTO GATT Agreement 111–12
WTO Technical Barriers to Trade (TBT Agreement) 126–7
non-governmental sources of information, communicable disease control 274–5
non-international armed conflict application, international humanitarian law 242–3
norm entrepreneurs 33, 432, 518–19
normative perspective
communicable disease control 269, 270
foundations 6–10
global governance 33–5
global governance mechanisms 37, 38–9
global governance, power types 46, 47
HIV recognition and evolution 304, 306–16, 324, 325, 326
human rights 88, 96, 97, 98–9, 100, 101
international environmental law 206, 215, 216, 217
international humanitarian law 244, 245, 248, 252, 255–6, 260–62
landscape on health 487–93, 513, 520, 521–2, 524, 526
non-communicable disease prevention 422–5
obesity and public health 431–2, 433, 444, 449
pharmaceutical standards
harmonization 463–8, 473–4
right to health 57, 69, 71, 72, 77
tobacco epidemic 350, 354, 355, 367–8, 369
Chemtura Corporation v Canada 181–3, 188, 191–2
Methanex v US 173, 180–81, 187–8, 192–3, 194
Norum, K 433
Norway, Philip Morris Norway v Health and Care Services of Norway 383, 385–6
Novak, G 249
Novella, S 314
Novogrodsky, N 315
Nunn, A 41
Nussbaum, M 6
obesity and public health 22, 427–59, 502–3
accountability mechanisms 439, 440–41, 445, 446
challenges 439–40
current global instruments 438–9
EU Law and obesity prevention 456–7
food industry involvement issues 440
global health governance 430–40
high in fat, salt and sugar (HFSS) foods 429, 436, 437, 448
international prevention measures 431–5
international prevention measures, obstacles to development 454–7
international trade and obesity prevention 455–6
legally binding instrument, need for 438–9
limitations of rights 451–4
lobbying and governmental resistance 433
normative perspective 431–2, 433, 444, 449
obesity causes 428–9
resources availability issues and state obligations 451
scientific evidence, need for 439–40
Small Island Developing States (SIDs) 411–12
soft law measures, call for 439
stigmatization and non-discrimination 453–4
sugar consumption and lack of voluntary targets 437–8
trans fats and lack of voluntary targets 438
UN Convention on the Rights of the Child (CRC) 446–50, 455
UN Sustainable Development Goals 434
WHO Commission on Ending Childhood Obesity (ECHO) 435
WHO Global Recommendations on Physical Activity for Health 436
WHO Global Strategy on Diet, Physical Activity and Health 433–4, 435–7
WHO Global Strategy on Noncommunicable Diseases 432–3, 435, 437, 438, 456
WHO mandate 430–32
obesity and public health, childhood obesity prevention 435, 436, 438, 446–51
environment-based approaches 448
parent and guardian responsibilities 450, 452
state obligations 448–9, 450–51
and stigmatization 453
obesity and public health, human rights 440–46
balancing 452–3
and commercial expression 452–3
right to adequate food 443–5
right to health 441–3, 452, 493
right to privacy and family life 452
state obligations 442–3
and stigmatization 453–4
obesity and public health, prevention measures 435–8
Codex Alimentarius Commission 436, 455–6
education and information 435–6
food composition and availability of healthy food 437–8
physical activity and environment 436
pricing and taxation 436–7, 438
Ó Cathaoir, K 13, 20, 22, 404, 419, 420, 427–59
occupation, legal regime of occupation and emergency law, international humanitarian law 248
Omole, O 49
O’Neill, O 71
Onzivu, W 201, 202, 207, 209
550  Research handbook on global health law

Ortino, F 414
Ottersen, P 30
Oxford Guidance on the Law relating to Humanitarian Relief Operations 251

Pan-American Health Organization 183, 379, 488
Pandemic Influenza Preparedness Framework (PIP Framework) 12–13
Panter-Brick, C 86
Paris Agreement intellectual property rights 137, 145
international environmental law 203, 227, 228
Paris Convention for the Protection of Industrial Property 136, 137
Paris Declaration on Aid Effectiveness 53
Patel, P 255
patents see intellectual property rights, patents
Patnaik, P 514
Patterson, D 390
Pauwelyn, J 4, 34, 491, 513, 520, 527
peace and security threat, and communicable disease control 291–2
Pearson Commission 53
Peel, J 207, 214, 215, 216, 217, 218, 219, 220
Pellegrino, E 60
Perelman, J 98, 101
Perlin, M 305
Permanent Court of Arbitration (PCA) 176
Iron Rhine 215, 218–19
Philip Morris v Australia 107–8, 170, 375
Petryna, A 88
pharmaceutical products generic names, intellectual property rights, trademarks 146
patents see intellectual property rights, patents, pharmaceutical products
pharmaceutical standards harmonization 22–3, 460–84, 489, 504–7, 511, 515, 520, 521, 524–5, 527
Agreement for the Unification of the Formulae of Potent Drugs 464
biological standardization 464–5
Brussels Agreement 464
European Directorate for the Quality of Medicines and HealthCare 473
future R&D recommendations 504–6, 511
good manufacturing practices 466
illicit trade in falsified medicines, convention proposal 506–8, 512
International Biological Preparations of Reference 471
International Chemical Reference Substances 470
International Conference of Drug Regulatory Authorities (ICDRA) 469–70
international nomenclatures 465–6
international normative development 463–8
International Pharmacopoeias and drugs analysis 464, 470, 473
marketing authorization 462, 463, 466–8
Permanent Standards Commission 465
physicochemical standards and laboratory tests 467, 472
secondary effects and adverse reactions 463
and trade liberalization 461
WHO Certification Scheme 473
WHO Collaborating Centre for International Pharmaceutical Vigilance (Uppsala Monitoring Centre (UMC)) 472–3
WHO Committee on Specifications for Pharmaceutical Preparations 470–71, 472
WHO Expert Committee on Biological Standardization 471–2
WHO International Pharmaceutical Vigilance Program 472
WHO Pharmaceutical Dictionary 473
WHO Programme on international non-proprietary names (INN) 465–6
pharmaceutical standards harmonization, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) 4–5, 461, 466, 467–8, 475–83, 489, 513, 521
allegations of lack of independence and subsequent reforms 478
ethics and human rights, and Declaration of Helsinki 476–7, 478
guideline implementation and productivity 476
‘international standard of reference’ 479–80
international trade impact and WTO Agreement on Technical Barriers to Trade (TBT) 479–83
openness improvements 481–2
regulatory members, classes of 481–3
technical standards 477–8
voting rights 482–3
WHO relationship 478
pharmaceutical standards harmonization, quality, safety and efficacy 462–3, 466–7
and technical standards 477
WHO action 468–74
WHO action, institutional aspects 469–70
WHO action, normative aspects 473–4
WHO expert committees and collaborating centres 470–73
Phelan, A 294
Phelan, J 453
Philippines, Department of Health v Mighty Corporation 384
philosophy contribution, right to health 59–61
physical activity and environment, obesity prevention measures 436
physical force mechanism, global governance 38, 42–3
physicochemical standards and laboratory tests, pharmaceutical standards harmonization 467, 472
Piot, P 85
Piwoz, E 12
poliomyelitis outbreak, communicable disease control 280
political philosophy and right to health 62–4
Pollack, M 520, 522, 523, 524, 525
Potts, H 40, 98
Prah Ruger, J 2, 5, 6, 7, 9
Prakash, A 49
precautionary principle international environmental law 219–20, 221, 230
WTO Sanitary and Phytosanitary Measures (SPS Agreement) 121–2
preferential trade agreements (PTAs), intellectual property rights 159–61
pregnancy bans, communicable disease control 284
preventative approach, international environmental law 217–19
prevention, HIV recognition and evolution 313–14, 318–19
Prevost, D 416
price factors
non-communicable disease prevention 407–8
obesity prevention measures 436–7, 438
Priest, N 441
production of global public goods (GPGs) 51–2, 54
Protocol on Water and Health 232
protracted violence context, international humanitarian law 242
Pruss-Ustun, A 200, 201, 202, 210
public health crises, human rights perspective 85–7
public health emergency of international concern (PHEIC)
communicable disease control 274–5, 276–7
communicable disease control, responses to declared 278–84, 285–6
public health grounds, justifying necessary trade-restrictive measures, and non-communicable disease prevention 412, 414–18
public health issues, right to health 68–9
public health measures, international investment law 166, 172–3, 177–9, 180–85
public health policy protection, tobacco epidemic 349
public international law 17–20
Puhl, R 429, 453, 454
Putnam, R 44
quality, safety and efficacy, pharmaceuticals see pharmaceutical standards
harmonization, quality, safety and efficacy
quarantine measures, communicable disease control 269, 270–71, 280, 282
ratchet clauses, WTO Technical Barriers to Trade (TBT Agreement) 133
Rayner, M 415
Redfield, P 86
regional free trade agreements, international investment law 167
regulatory market exclusivity, intellectual property rights 143–5
new biologic products 144–5
patents, distinction from 143–4
regulatory powers, international investment law 174, 177, 180, 187, 190, 194
regulatory review exception, patents, pharmaceutical products 154–5
Reichman, J 150, 157
Reisman, M 164, 186
relief operation consent, international humanitarian law 250–52
research and development (R&D) delinking R&D element from production and distribution elements 158–9
HIV recognition and evolution 308–9, 313–14
patents, pharmaceutical products 162–3
research materials, intellectual property rights, copyright 148
resource mobilization mechanism, global governance 38, 41–2
resources availability issues, and obesity and public health 451
respect principle international humanitarian law, wounded and sick 249–50
right to health 79
reverse engineering, trade secret protection 149
Riedel, E 447
right to adequate food 443–5
right to health 15–17, 56–81
AAAQ model and nature of entitlements 9, 70
autonomy and paternalism, tension between 67–9
conceptualization of health issues 78–9
criticisms of 63–4
design and delivery of global health initiatives 79–80
highest attainable standard of health, meaning of 64–5, 66–7, 69–70
HIV recognition and evolution 325, 330, 331, 334
holistic response, need for 80
human rights perspective, Gostin’s Global Health Law 93–6
individual’s moral value 78–9
and international law 59, 60, 62, 63, 71
interpretation concerns 65–6
justification for 58–9
meaning of 64–70
medical model and individual health outcomes 78
moral philosophy 61–2
normative perspective 57, 69, 71, 72, 77
obesity and public health, human rights contribution 441–3, 452, 493
philosophy contribution 59–61
political philosophy and practical consequences 62–4
principle of respect 79
public health issues 68–9
qualitative framework 70
social determinants of health 69–70
social model and disability discourse 78
right to health, state obligations 71–7
international cooperation and development of global health law 76–7
obligation to take appropriate measures 72–3
obligation to take specific measures 71–2
progressive realization and accountability 74–6
tripartite typology of obligations (respect, protect, fulfil) 73–4
right to privacy and family life 452
right to science 94
right to water 213
Rio Declaration, Agenda 21, and sustainable development 206,
disease control, health-security paradigm
Sekalala, S 4, 520, 523, 524
Sen, A 6, 61
Sethi, N 49
Seuba, X 4–5, 11, 22–3, 270, 460–84, 489, 513, 515, 521, 527
Shaffer, G 520, 522, 523, 524, 525
Shaw, M 7
Shiner, R 452
Shrank, W 146
Shubber, S 12
Shue, H 73
Sikkink, K 33, 517–18
Single Presentation Requirement (SPR), international investment law 184–5, 189, 194
Sisnormski, J 458
Sivakumaran, S 86–7, 242
Sizaret, P 464, 472
Slaughter, A-M 527
Sloane, R 164, 186
Small Island Developing States (SIDs), and obesity 411–12
Smith, T 314
Snidal, D 4, 511, 521
Snowdon, W 411
social determinants of health 69–70
social model, disability discourse and right to health 78
soft law standards 4–5, 8, 10, 12, 17 measures, call for, and obesity and public health 439
and normative landscape on health 489–92, 513, 520, 521–2, 524, 526
Sørensen, T 440
South Africa
British American Tobacco South Africa Ltd v Minister of Health 384, 385, 386
international exhaustion of patents rule 155, 156
sovereignty over natural resources, international environmental law 214–15
Spijkers, O 8
Sreenvasan, G 60
Sri Lanka, Ceylon Tobacco Company v Minister of Health 384
Srithar, D 24, 49, 90
standardization, biological, pharmaceutical standards harmonization 464–5
standstill clauses, WTO Technical Barriers to Trade (TBT Agreement) 133
state denials of existence of HIV 307, 308
state obligations
decision-making, and doctrines of deference, human rights perspective 97, 101–2
HIV recognition and evolution 317–19
obesity and public health, childhood obesity prevention 448–9, 450–51
obesity and public health, human rights 442–3
preventative approach, international environmental law 218
resources availability issues, obesity and public health 451
right to health see right to health, state obligations
States’ police and regulatory powers, international investment law 174, 177, 180, 187, 190, 194
Steele, S 410
stigmatization
childhood obesity prevention 453
HIV recognition and evolution 307–8, 323–4
obesity and public health 453–4
Stockholm Conference, international environmental law 197, 206, 207–9, 210, 213, 214, 217
Stockholm Convention on Persistent Organic Pollutant 226, 234
structural type, global governance, power types 45, 47
Stuttaford, M 14
sugar consumption and lack of voluntary targets, obesity and public health 437–8
Index 555

Sunstein, C 63, 403
sustainable development, international environmental law 203, 211, 215–17, 221
Suzuki, Y 469
Sweden, childhood obesity 443, 449
Swinburn, B 427, 429
swine flu pandemic, communicable disease control 279–80, 285–8
Syria, non-state armed groups and humanitarian assistance 261
Szeli, E 305
Szlezak, N 50

Tantivess, S. 41
Tarantola, D 13, 14, 20, 21, 303–39, 441, 492, 495
Tasioulas, J 60, 61, 62, 67, 69, 94
Tatlow-Golden, M 404
Taubman, A 526
taxation
non-communicable disease prevention 407–8
obesity prevention measures 436–7, 438
Taylor, A 345–6, 438, 439, 492, 502, 503
technical standards, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) 477–8
Tejima, Y 8
Terry, F 254
Thailand, JT International (Thailand) v Minister of Public Health 384
Thakur, R 27, 36
third parties prevented from using protected subject matter, and patents 142–3
Thirlway, H 7
Thomas, B 390, 497, 502
Thow, A 411, 412, 455, 456, 457
tobacco control
industry interference protection 399–400
legally binding global framework 394, 397–400
WHO Framework Convention on Tobacco Control (FCTC) 394, 397–9
tobacco epidemic 21–2, 340–88, 490, 495
global epidemic effects 343–4
global response 344–6
normative perspective 350, 354, 355, 367–8, 369
WHA resolution 340–41
WHO Tobacco Free Initiative 351
World No Tobacco Day 364
challenges, ongoing 367–9
commercial rights and interests in regional and domestic law 383–6
demand-reduction obligations 348–9
FCTC2030 programme 357
governance regime 347–58
and health sector control issues 368–9
human rights law 371–5
influence in other bodies of law 369–86
intellectual property rights 382
international cooperation and assistance obligations 349–50
international trade and investment law 375–83
MPOWER measures 366–7, 368
non-communicable diseases 359–61
non-communicable diseases, WHO Global NCD Action Plan 360
public health policy protection 349
successes 364–7
supply-reduction obligations 349
tobacco control and health and development agendas, integration of 358–64
and tobacco industry resources 368
treaty text 347–51
UN 2030 Sustainable Development Goals (SDGs) 341–2, 361–4
UN 2030 Sustainable Development Goals (SDGs), Addis Ababa Action Agenda 362–3 see also World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC)
tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC), Conference of the Parties (COP) 350, 351–6, 359, 361, 363, 379 activities to support and monitor 356–8
eliminate all forms of illicit trade in tobacco products 351–2
impact assessment expert group 364–8
implementation guidelines and declarations 352–4
implementation guidelines and declarations, status and effect 355–6, 373–4, 381–3
implementation review framework 357–8
UN human rights system cooperation 374–5
Tobin, J 7, 15, 16, 56–81, 419, 447
Tomasevski, K 307
Torres, M 323
trade agreements, preferential trade agreements (PTAs), intellectual property rights 159–61
trade law see international trade law
tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC), Conference of the Parties (COP) 350, 351–6, 359, 361, 363, 379
Tobin, J 7, 15, 16, 56–81, 419, 447
transboundary environmental impact assessment, international environmental law 221–3, 226–7
transfats and lack of voluntary targets, and obesity and public health 438
transparency policies communicable disease control 301
HIV recognition and evolution 321–5, 331
international investment law 177, 180, 191
WTO Technical Barriers to Trade (TBT Agreement) 128–9, 130–31
see also accountability mechanisms
travel restrictions, communicable disease control 280–83
Trebilcock, M 411, 416
tri-therapy effectiveness, HIV recognition and evolution 310–11
Troullier, P 467
Twersky, A 403
Twining, D 228
Twining, W 88
Uchkunova, I 170
UK
Alcohol (Minimum Pricing) (Scotland) Act 408
British American Tobacco v Secretary of State for Health 356, 399
R (British American Tobacco) v Secretary of State for Health 382, 384, 385, 386, 458
Scotch Whisky Association v The Lord Advocate 408, 416, 417, 458
trademarks see intellectual property rights, trademarks
Transatlantic Trade and Investment Partnership (TTIP) 107, 167, 196
trade liberalization non-communicable disease prevention 411–12
and pharmaceutical standards harmonization 461
trade secrets protection see intellectual property rights, trade secret protection
traffic light labelling scheme 403, 456
UN 2030 Agenda for Sustainable Development 389
UN 2030 Sustainable Development Goals (SDGs) 341–2, 361–4
UN action in response to global security threat, and communicable disease control 295–7
UN Commission on International Trade Law (UNCITRAL) 176
Eli Lilly v Canada 108, 160–61, 172, 173
Glamis Gold v US 173
International Thunderbird Gaming Corporation v The United Mexican States 174
Philip Morris v Australia 107–8, 170
Saluka Investments v The Czech Republic 169
UN Conference on Sustainable Development 211–12
UN Convention Against Illicit Traffic in Narcotic Drugs 512
UN Convention on Biological Diversity (CBD) 199–200, 209, 213–14, 220, 222–3, 228–9, 500, 501, 525
Cartagena Protocol on Biosafety 230–32
UN Convention on the Elimination of All Forms of Discrimination against Women (CEDAW) 371, 372
UN Convention on the Law of the Non-Navigational Uses of International Watercourses 233
UN Convention on the Protection and Use of Transboundary Watercourses and International Lakes 232
non-communicable disease prevention 419, 420, 421–2
obesity and public health 446–50, 455
UN Decade of Action on Nutrition 396
UN Environment Programme 234
UN Framework Convention on Climate Change (UNFCCC) 202–3, 209, 214, 227–8
UN Framework Convention on Global Health proposal 503–4
UN General Assembly Special Session (UNGASS) Declaration, HIV recognition and evolution 322–3
UN Guiding Principles on Business and Human Rights 48
UN High Level Meetings on NCD prevention 391–6
UN InterAgency Task Force on NCDs (IATF) 393
UN Millennium Development Goals, HIV recognition and evolution 317, 319
UN Program on HIV/AIDS (UNAIDS) 310, 311, 312, 313, 314, 317, 322–3, 523–4
National Commitments and Policy Instrument (NCPI) 322
UN Security Council and communicable disease control 292–7
Resolution 2286 (2016) on healthcare in armed conflict 255, 256, 260–61
UN Standard Minimum Rules for the Treatment of Prisoners 10
UN Sustainable Development Goals (SDGs) HIV recognition and evolution 319–20, 326
international environmental law 212, 217
obesity and public health 434
UN Water Conference 209
558 Research handbook on global health law

UNICEF, For a Child Rights-Based Approach to Food Marketing 419–20
universal access to medicines, WTO TRIPS Agreement 136, 153, 156, 157, 158
Unwin, N 412
US Food and Drug Administration (FDA) 31–2, 147, 477
free trade agreements 159–60
international exhaustion of patents rule 156
Medical Society Consortium on Climate and Health, Medical Alert 204
preferential trade agreements (PTAs) 159–60
President’s Emergency Plan for AIDS Relief (PEPFAR) 31, 312, 321
US, cases
Association for Molecular Pathology v Myriad Genetics 140
Holder v Humanitarian Law Project 259
Impression Products v Lexmark International 156
PLIVA v Mensing 147
Qualitex Co. v Jacobson Products 147
United States v Farhane 260
Wyeth v Levine 147

vaccines, and patents 139–40
Vadi, V 164
Valgaarda, S 429
Van den Bossche, P 416
Van Harten, G 175
Vandervelde, K 166
Vayena, E 60, 61, 62, 67, 69, 94
Venekiene, E 60
Venkatapuram, S 6–7, 9

Vergan, P 456
Vignes, C-H 12, 271, 431, 493, 515, 520
Vité, S 241
Vogel, D 464
voluntary formal norms, global governance 33–4
voluntary industry commitments, non-communicable disease prevention 409
Von Tigerstrom, B 416
Voon, T 390, 412–13
voting rights, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) 482–3
vulnerability-reduction responses, HIV recognition and evolution 309, 311–12

Waddell, S 42
Waibel, M 166, 175, 196
Walker, N 88
Waltman, S 8, 18, 19, 197–238, 488
Wansink, B 403
Water Charters, international environmental law 234
water contamination, international environmental law 204–5, 209
Waters, E 440
Watson, A 423
Webb, P 395
Weber, M 42
Weil, P 491
Weiss, T 27, 36
well-being, and human health, international environmental law 198, 200, 202, 208, 209, 210, 212, 231, 232–3, 234
White, L 98, 101
Whitty, N 87
Wiley, L 82, 104
Wilke, M 491
Wills, J 403
Wolf, J 200, 201, 202, 210
Wolf, L 307
Wolf, J 57, 60, 62–3, 81
World Health Assembly (WHA) 10–12
communicable disease control 273–8
tobacco epidemic 340–41
World Health Organization (WHO) 2–3, 4, 6, 10–13
2030 Agenda for Sustainable Development 395–6
Certification Scheme, pharmaceutical standards 473
Code of Practice on the International Recruitment of Health Personnel 34, 48, 487, 523
Code of Practice on the Marketing of Breast milk Substitute 34, 406, 515
Codex Alimentarius Commission 123, 436, 455–6, 489, 490, 498, 521, 526
Collaborating Centre for International Pharmaceutical Vigilance (Uppsala Monitoring Centre (UMC)) 472–3
Commission on Ending Childhood Obesity (ECHO) 435
Committee on Biological Standardisation 464–5
Committee on Specifications for Pharmaceutical Preparations 470–71, 472
Ending Childhood Obesity Commission 407, 412, 418
expert committees and collaborating centres, pharmaceutical standards harmonization 470–73
Framework Convention on Tobacco Control (FCTC) 11, 24–5, 34, 39, 72–3, 127, 183–4, 194, 394, 448, 487
Framework Convention on Tobacco Control (FCTC), non-communicable disease prevention 394, 397–9
Framework Convention on Tobacco Control (FCTC), tobacco epidemic see tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC)
Framework for Engagement with Non-State Actors (FENSA) 399, 526
Global Action Plan, communicable disease control 498–9
Global Action Plan, non-communicable disease prevention 392–3, 394, 401, 404, 407, 409
Global Conference on Health and Climate 228
Global Coordination Mechanism on NCDs (GCM/NCD) 393–4
Global NCD Action Plan, tobacco epidemic, WHO Framework Convention on Tobacco Control (FCTC) 360
Global Recommendations on Physical Activity for Health 436
Global Strategy on Diet and Physical Activity, non-communicable disease prevention 408–9
Global Strategy on Diet and Physical Activity, obesity and public health 433–4, 435–7
Global Strategy on Noncommunicable Diseases, obesity and public health 432–3, 435, 437, 438, 456
Global Strategy to Reduce the Harmful Use of Alcohol 405–6, 408–9
HIV Progress report 315, 316, 323
HIV recognition and evolution, discord and setbacks 313
and intellectual property rights 158–9
and International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) 478
international environmental law report 200–201, 202
International Health Regulations see International Health Regulations (IHR)
International Pharmaceutical Vigilance Program 472
obesity and public health mandate 430–32
Pandemic Influenza Preparedness (PIP) Framework 34
pharmaceutical standards harmonization, quality, safety and efficacy 468–74
Programme on international non-proprietary names (INN) 465–6
Special Programme on AIDS 308–9, 313, 314
Tobacco Free Initiative 351
World Intellectual Property Organization (WIPO) 158
Madrid Agreement and Protocol (Madrid System) 137
Patent Cooperation Treaty (PCT) 137
World No Tobacco Day 364
World Organization for Animal Health (OIE) 124
World Summit on Sustainable Development 211
World Trade Organization (WTO)
GATS Agreement see international trade law, WTO GATS Agreement
GATT Agreement see international trade law, WTO GATT Agreement
and non-communicable disease prevention 415–16
SPS Agreement see international trade law, WTO Sanitary and Phytosanitary Measures (SPS Agreement)
TBT Agreement see international trade law, WTO Technical Barriers to Trade (TBT Agreement)
TRIPS Agreement see intellectual property rights, WTO TRIPS Agreement
TRIPS Agreement and international trade law 105, 106
World Trade Organization (WTO)
Dispute Settlement
Australia – Salmon 120
Australia – Tobacco Plain Packaging 106, 107, 116, 127–8, 155, 376, 380–81
Brazil – Tyres 105, 112, 113, 115, 116, 117, 418
Canada – Pharmaceutical Patents 106, 154–5
China – Poultry 106
EC – Asbestos 105, 111, 113, 114, 116, 117, 122, 125
EC – Biotech 106, 231
EC – Hormones 106, 119, 121, 122–3
EC – Meat and Meat Products 220
EC – Sardines 114
EC – Seal Products 110, 111
EU – Seizure of Generic Drugs in Transit 106
India – Agricultural Products 106, 124, 154
India – Patents 106
international trade law 105–7
Japan – Agricultural Products 119
Japan – Apples 121
Korea – Beef 114
Thailand – Cigarettes 112, 115
US – Clove Cigarettes 106, 126, 127, 380, 414
US – Gambling 114, 132
US – Gasoline 115, 116, 117
Index 561

US – Poultry 124–5

US – Tuna 115, 414

wounded and sick protection law see international humanitarian law, wounded and sick

Yamin, A 79, 83, 84, 102
Yannaca-Small, K 175
Yearwood, A 412

Yemen, cholera epidemic 43
Young, K 98, 101, 102

Zidar, A 279
Zika virus outbreak 283–4
Zuniga, J 57, 82